Pasithea Therapeutics (KTTA) Retained Earnings (2020 - 2026)
Pasithea Therapeutics recorded quarterly Retained Earnings of -$72.9 million in Q1 2026, down 4.13% quarter-over-quarter from -$70.0 million in Q4 2025, and down 37.17% year-over-year from -$116.0 million in Q1 2025.
Pasithea Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$72.9 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 37.17% year-over-year to -$72.9 million; the TTM figure through Mar 2026 stood at -$72.9 million (down 37.17% YoY), while the FY2025 annual figure was -$70.0 million, down 976199.83% from the prior year.
- Retained Earnings came in at -$72.9 million for Q1 2026 at Pasithea Therapeutics, down from -$70.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $18301.0 in Q3 2025 to a low of -$72.9 million in Q1 2026.
- A 5-year average of -$27.5 million and a median of -$22.9 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings sank 1243633.81% in 2024 and jumped 100.04% in 2025, its largest moves.
- Pasithea Therapeutics' Retained Earnings stood at -$19.4 million in 2022, then plunged by 82.46% to -$35.3 million in 2023, then jumped by 99.98% to -$7171.0 in 2024, then slumped by 976199.83% to -$70.0 million in 2025, then fell by 4.13% to -$72.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$72.9 million, -$70.0 million, and $18301.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -72.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.90 Mn |
| Dec 31, 2025 | -70.01 Mn |
| Sep 30, 2025 | -59.90 Mn |
| Jun 30, 2025 | 5,631.00 |
| Mar 31, 2025 | -53.10 Mn |
| Dec 31, 2024 | -7,171.00 |
| Sep 30, 2024 | -46.40 Mn |
| Jun 30, 2024 | -8,184.00 |
| Mar 31, 2024 | -5,272.00 |
| Dec 31, 2023 | -35.32 Mn |
| Sep 30, 2023 | -30.27 Mn |
| Jun 30, 2023 | -26.66 Mn |
| Mar 31, 2023 | -22.89 Mn |
| Dec 31, 2022 | -19.36 Mn |
| Sep 30, 2022 | -146,573.00 |
| Jun 30, 2022 | -6.45 Mn |
| Mar 31, 2022 | -15,074.00 |
| Dec 31, 2021 | -10,561.00 |
| Sep 30, 2021 | -3,762.00 |
| Dec 31, 2020 | -40,984.00 |